구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | trastuzumab (Herceptin, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab) Roche / Genentech·Advanced Breast Carcinoma 15 trials |
|---|---|
Overview Program | Hyaluronidase-zzxf/Pertuzumab/Trastuzumab |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | Advanced Breast Carcinoma |
Overview Indication | Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.. To characterize pertuzumab pharmacokinetics (PK) in FeDeriCa (NCT03493854: fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection [PH FDC SC] v… |
Clinical Safety signal | Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.. To characterize pertuzumab pharmacokinetics (PK) in FeDeriCa (NCT03493854: fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection [PH FDC SC] v… |
Clinical Selected reported efficacy | ORR 50% |
Clinical Reported ORR | 50% |
Clinical Result source | ClinicalTrials.gov NCT05730712 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT05730712 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | trastuzumab (Herceptin, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab) Roche / Genentech·Advanced Breast Carcinoma 15 trials |
|---|---|
Overview Program | Hyaluronidase-zzxf/Pertuzumab/Trastuzumab |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | Advanced Breast Carcinoma |
Overview Indication | Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.. To characterize pertuzumab pharmacokinetics (PK) in FeDeriCa (NCT03493854: fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection [PH FDC SC] v… |
Clinical Safety signal | Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.. To characterize pertuzumab pharmacokinetics (PK) in FeDeriCa (NCT03493854: fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection [PH FDC SC] v… |
Clinical Selected reported efficacy | ORR 50% |
Clinical Reported ORR | 50% |
Clinical Result source | ClinicalTrials.gov NCT05730712 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT05730712 |
추천 비교
추천 비교